Loading
A phase 2/3 trial of Disitamab vedotin, Gemcitabine, Capecitabine, Trastuzumab and Inetetamab in HER2-positive breast cancer and Breast cancer, run by Fudan University, not yet recruiting.
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure is a phase 2/3 interventional study registered as NCT07366840 by Fudan University, with 268 participants planned, started 2026-01-16 and due to reach its primary completion in 2028-01-16. Interventions recorded: Disitamab Vedotin, Gemcitabine, Capecitabine, Trastuzumab, Inetetamab. Conditions recorded: HER2-positive Breast Cancer, Metastatic Breast Cancer.
Linked to the drug Inetetamab because the registry names it among its interventions and HER2-positive breast cancer and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
Shares Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Shares Disitamab vedotin, Trastuzumab, Capecitabine and the tag pipeline.
Shares Trastuzumab, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Shares Trastuzumab, HER2-positive breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
Shares Trastuzumab, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/